Don't pick the loser: Lessons from the GeparQuinto trial

The Lancet Oncology

Volumn 13, Issue 2, 2012, Pages 112-113

  Chia, Stephen K ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; LAPATINIB; TRASTUZUMAB;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL RESEARCH; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; LETTER; LYMPH NODE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL, HUMANIZED; BREAST NEOPLASMS; FEMALE; HUMANS; QUINAZOLINES;

EID: 84856489940     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(12)70013-X     Document Type: Letter

References (8)

1. Untch M, Loibl S, Bischoff J, et al. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol 2012, for the German Breast Group (GBG) and the Arbeitsgemeinschaft Gynäkologische Onkologie-Breast (AGO-B) Study Group, published online Jan 17. 10.1016/S1470-2045(11)70397-7.
2. Chia S, Swain SM, Byrd DR, et al. Locally advanced and inflammatory breast cancer. J Clin Oncol 2008, 26:786-790.
3. Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 2008, 26:778-785.
4. Fischer B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998, 16:2672-2685.
5. Dowsett M, Smith IE, Ebbs SR, et al. Short term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrazole, or tamoxifen alone or combined correlate with recurrence free survival. Clin Cancer Res 2005, 11:951-958s.
6. Baum M, Budzar U, Cuzick J, et al. Anastrazole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of post-menopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002, 359:2131-2139.
7. Baselga J, Bradbury I, Eidtmann H, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 2012, on behalf of the NeoALTTO Study Team, published online Jan 17. 10.1016/S0140-6736(11)61847-3.
8. Gianni L, Pienkowski T, Im Y-H, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012, 13:25-32.